viewHorizon Discovery Group PLC

Horizon Discovery Gp - Notice of Trading Update & Capital Markets Webinar

RNS Number : 3177S
Horizon Discovery Group plc
08 July 2020


Horizon Discovery Group plc


Notice of Trading Update and Capital Markets Webinar



Cambridge, UK, 08 July 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", or "the Company"), a cell engineering company focused on commercialising the application of gene editing and gene modulation, announces that it will issue an unaudited pre-close trading update on Wednesday, 29 July 2020 and host a Capital Markets Webinar for institutional investors and analysts at 15:00pm BST on the same day.


A detailed agenda and instructions to participate virtually will be available via the Company's website closer to the event.


A copy of the presentations and a recording of the webinar will be made available on the Company's website shortly afterwards.


No new material information will be provided outside of the trading update.





For further information from Horizon Discovery Group plc, please contact:


Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Jon Davies, Head of Investor Relations

Tel: +44 (0) 1223 655 580


Numis Securities Limited (Broker and NOMAD)

Freddie Barnfield / Duncan Monteith

Tel: +44 (0) 207 260 1000


Consilium Strategic Communications (Financial Media and UK Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5700

Email: [email protected]


Westwicke, an ICR Company (US Investor Relations)

Stephanie Carrington

Tel. +1 646-277-1282

Email: [email protected]



About Horizon Discovery Group plc www.horizondiscovery.com


Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development. Horizon's portfolio of tools and services is built on decades of experience in altering the expression of genes across mammalian and human cell types to provide cell engineering tools and services to customers in three key areas of the therapeutic ecosystem: basic research, drug discovery and development and therapeutic applications. Horizon's offerings support and enable critical elements of the drug development and therapeutic value chain, particularly in the area of precision medicine. Horizon's customers include biopharmaceutical and diagnostics companies, contract research and manufacturing organisations and academic researchers across the globe.


Horizon is headquartered in Cambridge, UK with offices in USA and Japan.  The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Horizon Discovery Group PLC

Price: 95.8

Market: AIM
Market Cap: £151.34 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Acquisition gives Horizon Discovery a 'full and complete suite of tools' to...

Chris Claxton, VP Investor Relations & Corporate Communications at Horizon Discovery Group PLC (LON:HZD), discusses with Proactive their 'transformational' acquisition of GE healthcare business Dharmacon. The US$85mln deal was announced in July and funded through cash and shares and...

on 4/9/17

3 min read